Hair loss and weight gain have not been reported as side effects of Mestinon. Patients should talk with their healthcare team in case they experience unusual symptoms while on treatment.
FAQs
As each person is unique and can respond differently to treatment, there is no standard timeline for when Mestinon starts to work. But the therapy has been reported to take about 20-30 minutes to have a clinical effect. Mestinon’s therapeutic effects last for…
Because Mestinon can increase the contraction of the eye’s pupil, it may cause blurred vision and reduce the sharpness of a person’s eyesight. Patients are advised not to drive or operate machines until they know how the therapy affects their vision, and to avoid these activities altogether if it does…
No well-controlled studies of Mestinon have included pregnant patients, so it is unclear whether the therapy is safe to use during pregnancy. Patients who are pregnant or plan to become pregnant while on Mestinon should discuss this with their doctor.
The U.S. Food and Drug Administration (FDA) approved Mestinon in 1955 as an oral tablet for the treatment of myasthenia gravis. Other formulations have been developed since then, including extended-release tablets, syrups, and injectable forms.
Changes in weight and hair loss have not been reported in clinical trials testing Soliris in people with generalized myasthenia gravis. However, some patients receiving the medication in other clinical trials have reported hair loss. Patients who experience unusual symptoms while on treatment should discuss these with their care…
In the REGAIN trial, which supported Soliris’ approval for myasthenia gravis, the majority of patients responded to treatment and experienced clinically meaningful improvements in the first three months. However, each patient is unique and may respond differently to the medication. A discussion with a healthcare provider can help…
Soliris has little to no impact on a person’s ability to drive and use machines. Yet, patients should be careful when attempting to drive or use machines before they know exactly how the medication affects them. Those taking Soliris should speak with their healthcare providers to know more about how…
While animal data has suggested that anti-C5 antibodies like Soliris can cause fetal harm, an analysis involving more than 300 women exposed to Soliris during pregnancy has not identified any major concerns. Still, it remains unknown if Soliris can cause harm to a developing human fetus, so patients who become…
The U.S. Food and Drug Administration (FDA) initially approved Soliris in 2017 to treat adults with generalized myasthenia gravis (gMG) who are positive for antibodies against the acetylcholine receptor (AChR). That marked the first approval for the disease in the U.S. in more than 60 years. In 2025, the FDA…
Recent Posts
- Regaining control over life when MG weighs me down
- New US patient registry to track MG using real-world data
- Standard treatments don’t always work for triple-seronegative MG
- Exercise, breathing training may help ease myasthenia gravis symptoms
- I learn asking for help means choosing not to do everything the hard way